Clinical Trial Update: An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours [Phase 2]

View source ↗

Summary

Open-label Phase 2 registry study evaluating Lu-DOTA-TATE in patients with somatostatin receptor–positive neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Lu-DOTA-TATE (Lutetium-177 DOTATATE) (Lutetium-177 DOTATATE)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: UNKNOWN